Prenatal genetic test company Ariosa Diagnostics files for a $69 million IPO
Ariosa Diagnostics, which provides genetic testing of fetal conditions and characteristics for expectant mothers, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering. The San Jose, CA-based company, which was founded in 2008 and booked $53 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol AROS. J.P. Morgan and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.